TURTLE CAMERON (Chief Business Officer) sold 12.4% of their position (10K shares) of EIDOS THERAPEUTICS, INC. on the open market
Open‑market sale worth $399.4K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 3 sales
Filed: 8/5/2020ACC: 0000899243-20-021565
Officer· Chief Business Officer
Since Nov 2018
-10K
Net shares
Net seller
$399.4K
Total sold
3
Open market trades
0B · 3S
5
Total transactions
5K acquired · 15K disposed
Non-Derivative Transactions4
Common Stock
Direct
Shares
+5K
Price / share
$13.20
Trade value
$66K
% of position
6.6%
8/3/2020
75.53K→80.53K
Common Stock
Direct
Shares
−2.80K
Price / share
$39.05
Trade value
$109.33K
% of position
3.5%
8/3/2020
80.53K→77.73K
Common Stock
Direct
Shares
−6.70K
Price / share
$40.25
Trade value
$269.67K
% of position
8.6%
8/3/2020
77.73K→71.03K
Common Stock
Direct
Shares
−500.00
Price / share
$40.89
Trade value
$20.45K
% of position
0.7%
8/3/2020
71.03K→70.53K
Total
Net shares
−5K
Net value
-$333.45K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 8/3/2020 | M · Option Exercise | +5K | $13.20 | $66K | 6.6% | 75.53K | 80.53K |
| Common Stock Direct | 8/3/2020 | S · Sale | −2.80K | $39.05 | $109.33K | 3.5% | 80.53K | 77.73K |
| Common Stock Direct | 8/3/2020 | S · Sale | −6.70K | $40.25 | $269.67K | 8.6% | 77.73K | 71.03K |
| Common Stock Direct | 8/3/2020 | S · Sale | −500.00 | $40.89 | $20.45K | 0.7% | 71.03K | 70.53K |
| Total | −5K | -$333.45K | ||||||
Derivative Transactions1
Stock Option (Right to Buy)
Direct
Converts to
Common Stock
5K shares
Shares
−5K
Strike price
13.20
Held after
80K
Exercisable
—
8/3/2020
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock5K shares | 8/3/2020 | M · Option Exercise | −5K | 13.20 | — | 80K |